D.G. Downey

7.6k total citations · 1 hit paper
94 papers, 1.4k citations indexed

About

D.G. Downey is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Molecular Biology. According to data from OpenAlex, D.G. Downey has authored 94 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Pulmonary and Respiratory Medicine, 18 papers in Epidemiology and 12 papers in Molecular Biology. Recurrent topics in D.G. Downey's work include Cystic Fibrosis Research Advances (69 papers), Neonatal Respiratory Health Research (21 papers) and Tracheal and airway disorders (17 papers). D.G. Downey is often cited by papers focused on Cystic Fibrosis Research Advances (69 papers), Neonatal Respiratory Health Research (21 papers) and Tracheal and airway disorders (17 papers). D.G. Downey collaborates with scholars based in United Kingdom, United States and Ireland. D.G. Downey's co-authors include J.S. Elborn, Scott C. Bell, Rosemary Lever, Rona M. MacKie, John E. Moore, Lorraine Martin, Diana Bilton, Michal Shteinberg, Clifford C. Taggart and Mary T. Keogan and has published in prestigious journals such as The Lancet, Nature Communications and The Journal of Physiology.

In The Last Decade

D.G. Downey

86 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Future therapies for cystic fibrosis

2023 71 citations Lucy Allen, D.G. Downey et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D.G. Downey United Kingdom	20	884	249	175	164	151	94	1.4k
Antje Schuster Germany	25	1.1k 1.2×	216 0.9×	163 0.9×	185 1.1×	1.0k 6.8×	74	2.1k
Nicholas S. Jones United Kingdom	25	276 0.3×	239 1.0×	121 0.7×	102 0.6×	488 3.2×	69	2.0k
Peter Oluf Schiøtz Denmark	31	754 0.9×	397 1.6×	219 1.3×	243 1.5×	515 3.4×	100	2.3k
Kawa Amin Sweden	19	375 0.4×	237 1.0×	149 0.9×	66 0.4×	732 4.8×	49	1.7k
Soichiro Kanoh Japan	17	617 0.7×	211 0.8×	28 0.2×	321 2.0×	300 2.0×	62	1.4k
G.G. Einarsson United Kingdom	18	776 0.9×	523 2.1×	84 0.5×	242 1.5×	162 1.1×	56	1.6k
Steven Haenen Belgium	12	263 0.3×	158 0.6×	50 0.3×	42 0.3×	183 1.2×	23	749
Paul McNally Ireland	26	1.0k 1.1×	432 1.7×	25 0.1×	197 1.2×	113 0.7×	78	1.7k
Berislav Bošnjak Germany	20	182 0.2×	246 1.0×	42 0.2×	123 0.8×	240 1.6×	42	1.1k
Harumi Suzaki Japan	24	443 0.5×	210 0.8×	156 0.9×	250 1.5×	666 4.4×	126	1.9k

Countries citing papers authored by D.G. Downey

Since Specialization

Citations

This map shows the geographic impact of D.G. Downey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.G. Downey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.G. Downey more than expected).

Fields of papers citing papers by D.G. Downey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.G. Downey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.G. Downey. The network helps show where D.G. Downey may publish in the future.

Co-authorship network of co-authors of D.G. Downey

This figure shows the co-authorship network connecting the top 25 collaborators of D.G. Downey. A scholar is included among the top collaborators of D.G. Downey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.G. Downey. D.G. Downey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brown, Jeremy, Darius Armstrong‐James, Jonathan Ayling-Smith, et al.. (2025). British Thoracic Society Clinical Statement onAspergillus-related chronic lung disease. Thorax. 80(Suppl 1). 3–21. 1 indexed citations

Frost, Freddy, D. Peckham, Robert D. Gray, et al.. (2025). Managing an ageing cystic fibrosis population: challenges and priorities. European Respiratory Review. 34(176). 240261–240261.

Sherrard, Laura J., G.G. Einarsson, Lieven Dupont, et al.. (2024). Inhaled antimicrobial prescribing for Pseudomonas aeruginosa infections in Europe. Journal of Cystic Fibrosis. 23(3). 499–505. 5 indexed citations

Downey, D.G., et al.. (2024). Bridging the gap: Challenging lung infections and clinical trial development in cystic fibrosis. Journal of Cystic Fibrosis. 24(1). 79–82. 1 indexed citations

Reihill, James, et al.. (2024). The effect of triple CFTR modulator therapy and azithromycin on ion channels and inflammation in cystic fibrosis. ERJ Open Research. 10(6). 502–2024. 1 indexed citations

Einarsson, G.G., Laura J. Sherrard, Joseph Hatch, et al.. (2023). Longitudinal changes in the cystic fibrosis airway microbiota with time and treatment. Journal of Cystic Fibrosis. 23(2). 252–261. 2 indexed citations

Einarsson, G.G., et al.. (2023). Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmonary exacerbations. European Respiratory Journal. 63(2). 2301228–2301228. 5 indexed citations

Taylor‐Cousar, Jennifer L., Paul D. Robinson, Michal Shteinberg, & D.G. Downey. (2023). CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. The Lancet. 402(10408). 1171–1184. 68 indexed citations

Bradley, Judy, Kathryn M. Ferguson, Katherine O’Neill, et al.. (2022). Clinimetric Properties of Outcome Measures in Bronchiectasis. Annals of the American Thoracic Society. 20(5). 648–659. 2 indexed citations

10.

Golec, Anita, Iwona Pranke, Paolo Scudieri, et al.. (2022). Isolation, cultivation, and application of primary respiratory epithelial cells obtained by nasal brushing, polyp samples, or lung explants. STAR Protocols. 3(2). 101419–101419. 6 indexed citations

11.

Chmiel, James F., Patrick A. Flume, D.G. Downey, et al.. (2020). Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. Journal of Cystic Fibrosis. 20(1). 78–85. 58 indexed citations

12.

Heijerman, Harry, D.G. Downey, Marcus Mall, et al.. (2019). Phase 3 efficacy and safety of the ELX/TEZ/IVA triple combination in people with CF homozygous for the F508DEL mutation. Ghent University Academic Bibliography (Ghent University). 2 indexed citations

13.

Sherrard, Laura J., G.G. Einarsson, Katherine O’Neill, et al.. (2019). Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis. Journal of Cystic Fibrosis. 18(6). 808–816. 14 indexed citations

14.

Moore, John E., et al.. (2018). Antimicrobial effect of dimethyl sulfoxide and N, N-Dimethylformamide on Mycobacterium abscessus: Implications for antimicrobial susceptibility testing. International Journal of Mycobacteriology. 7(2). 134–134. 29 indexed citations

15.

Moore, John E., et al.. (2018). Antimycobacterial activity of nonantibiotics associated with the polypharmacy of cystic fibrosis (CF) against mycobacterium abscessus. International Journal of Mycobacteriology. 7(4). 358–358. 5 indexed citations

16.

Taylor‐Cousar, Jennifer L., Nico Derichs, D. Elizabeth Tullis, et al.. (2017). Safety, Tolerability and early signs of efficacy with riociguat for the treatment of adult PHE508DEL homozygous cystic fibrosis patients: safety data from the RIO-CF study. Pediatric Pulmonology. 52. 1 indexed citations

17.

Reid, Anna, et al.. (2014). WS20.6 The use of LCI as an effective tool for monitoring clinical response to ivacaftor therapy in CF patients with at least one G551D-allele. Journal of Cystic Fibrosis. 13. S40–S40. 1 indexed citations

18.

Tunney, Michael M., Émilie Vallières, S. McGrath, et al.. (2014). Inflammatory biomarkers in urine of cystic fibrosis patients. European Respiratory Journal. 44(Suppl 58). P1208–P1208. 1 indexed citations

19.

Hester, Katy, Tom Powell, D.G. Downey, J.S. Elborn, & N.A. Jarad. (2007). Glucocorticoids as an adjuvant treatment to intravenous antibiotics for cystic fibrosis pulmonary exacerbations: A UK Survey. Journal of Cystic Fibrosis. 6(4). 311–313. 9 indexed citations

20.

Martin, Lorraine, et al.. (2006). Serine proteinase inhibitor therapy in alpha(1)-antitrypsin inhibitor deficiency and cystic fibrosis.. Pediatric Pulmonology. 41(2). 363–375. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact